Eris Lifesciences Share Price
Start SIP in Eris Lifesciences
Start SIPEris Lifesciences Performance
Day Range
- Low 1,379
- High 1,413
52 Week Range
- Low 804
- High 1,522
- Open Price1,389
- Previous Close1,389
- Volume151019
Eris Lifesciences Investment Rating
-
Master Rating:
-
Eris Lifesciences has an operating revenue of Rs. 2,262.24 Cr. on a trailing 12-month basis. An annual revenue growth of 20% is outstanding, Pre-tax margin of 21% is great, ROE of 15% is good. The company has a reasonable debt to equity of 25%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 15% and 41% from 50DMA and 200DMA. From an O'Neil Methodology perspective, the stock has an EPS Rank of 49 which is a POOR score indicating inconsistency in earnings, a RS Rating of 76 which is FAIR indicating the recent price performance, Buyer Demand at A which is evident from recent demand for the stock, Group Rank of 75 indicates it belongs to a poor industry group of Medical-Biomed/Biotech and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment.
EPS Strength
Price Strength
Buyer Demand
Group Rank
| Indicator | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 |
|---|---|---|---|---|---|---|
| Oper Rev Qtr Cr | 449 | 332 | 316 | 410 | 411 | 308 |
| Operating Expenses Qtr Cr | 333 | 262 | 250 | 265 | 256 | 203 |
| Operating Profit Qtr Cr | 123 | 79 | 74 | 144 | 156 | 111 |
| Depreciation Qtr Cr | 46 | 29 | 28 | 25 | 20 | 17 |
| Interest Qtr Cr | 56 | 29 | 15 | 7 | 7 | 3 |
| Tax Qtr Cr | 10 | 2 | 3 | 2 | 22 | 8 |
| Net Profit Qtr Cr | 17 | 40 | 32 | 118 | 111 | 88 |
Eris Lifesciences Technicals
EMA & SMA
- Bullish Moving Average
- ___
- 11
- Bearish Moving Average
- ___
- 5
- 20 Day
- ₹1,369.62
- 50 Day
- ₹1,248.71
- 100 Day
- ₹1,133.99
- 200 Day
- ₹1,021.85
- 20 Day
- ₹1,378.31
- 50 Day
- ₹1,210.36
- 100 Day
- ₹1,078.19
- 200 Day
- ₹981.51
Eris Lifesciences Resistance and Support
| Resistance | |
|---|---|
| First Resistance | 1,411.85 |
| Second Resistance | 1,429.65 |
| Third Resistance | 1,445.85 |
| RSI | 62.05 |
| MFI | 61.52 |
| MACD Single Line | 75.23 |
| MACD | 62.34 |
| Support | |
|---|---|
| First Support | 1,377.85 |
| Second Support | 1,361.65 |
| Third Supoort | 1,343.85 |
Eris Lifesciences Delivery and Volume
| Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
|---|---|---|---|
| Day | 155,277 | 9,333,700 | 60.11 |
| Week | 185,504 | 9,596,143 | 51.73 |
| 1 Month | 239,759 | 10,652,502 | 44.43 |
| 6 Month | 216,626 | 13,053,907 | 60.26 |
Eris Lifesciences Result Highlights
Eris Lifesciences Synopsis
NSE-Medical-Biomed/Biotech
Eris Lifesciences is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 1330.73 Cr. and Equity Capital is Rs. 13.60 Cr. for the Year ended 31/03/2023. Eris Lifesciences Ltd. is a Public Limited Listed company incorporated on 25/01/2007 and has its registered office in the State of Gujarat, India. Company’s Corporate Identification Number(CIN) is L24232GJ2007PLC049867 and registration number is 049867.| Market Cap | 18,908 |
| Sales | 1,532 |
| Shares in Float | 6.12 |
| No of funds | 147 |
| Yield |
| Book Value | 7.49 |
| U/D Vol ratio | 1.3 |
| LTDebt / Equity | 19 |
| Alpha | 0.16 |
| Beta | 0.51 |
Eris Lifesciences Shareholding Pattern
| Owner Name | Jun-24 | Mar-24 | Dec-23 | Sep-23 |
|---|---|---|---|---|
| Promoters | 54.88% | 54.9% | 54.9% | 54.91% |
| Mutual Funds | 14.52% | 14.92% | 13.85% | 13.86% |
| Insurance Companies | 0.9% | |||
| Foreign Portfolio Investors | 14.59% | 14.27% | 13.13% | 13.2% |
| Financial Institutions/ Banks | ||||
| Individual Investors | 13.53% | 14.24% | 15.67% | 15.47% |
| Others | 1.58% | 1.67% | 2.45% | 2.56% |
Eris Lifesciences Management
| Name | Designation |
|---|---|
| Mr. Amit Bakshi | Chairperson & Managing Director |
| Mr. Krishnakumar Vaidyanathan | COO & Executive Director |
| Mr. Inderjeet Singh Negi | Executive Director |
| Mr. Kaushal Shah | Executive Director |
| Mr. Rajeev Dalal | Independent Director |
| Mr. Vasudevan Sujesh | Independent Director |
| Ms. Kalpana Unadkat | Independent Director |
| Mr. Prashant Gupta | Independent Director |
Eris Lifesciences Forecast
Price Estimates
Eris Lifesciences Corporate Action
| Date | Purpose | Remarks |
|---|---|---|
| 2024-08-02 | Quarterly Results | |
| 2024-05-21 | Audited Results & Fund Raising | |
| 2024-02-13 | Quarterly Results | |
| 2023-11-08 | Quarterly Results | |
| 2023-08-07 | Quarterly Results |
| Date | Purpose | Remarks |
|---|---|---|
| 2022-08-16 | INTERIM | Rs.7.35 per share(735%)Interim Dividend |
| 2021-08-06 | INTERIM | Rs.6.01 per share(601%)Interim Dividend |
Eris Lifesciences FAQs
What is Share Price of Eris Lifesciences ?
Eris Lifesciences share price is ₹1,394 As on 18 September, 2024 | 02:24
What is the Market Cap of Eris Lifesciences ?
The Market Cap of Eris Lifesciences is ₹18970.4 Cr As on 18 September, 2024 | 02:24
What is the P/E ratio of Eris Lifesciences ?
The P/E ratio of Eris Lifesciences is 49.9 As on 18 September, 2024 | 02:24
What is the PB ratio of Eris Lifesciences ?
The PB ratio of Eris Lifesciences is 5.9 As on 18 September, 2024 | 02:24